A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Recruiting now · Phase 2

Conditions studied: Colorectal Cancer

In brief

This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.

Key facts

Study ID

NCT07235293

Run by

Kahr Bio Australia Pty Ltd

People needed

90

Starts

2026-01-16

Expected to finish

2027-04-30

Last updated by the study team

2026-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are ≥ 18 years of age with a life expectancy of > 3 months.
• Participants with histologically confirmed, inoperable, MSS and/or pMMR CRC which has progressed to, or is intolerant to, specified therapies (and has received prior treatment with no more than 3 lines of therapy).
• Measurable disease per RECIST v1.1.

You may not qualify if…

• Central nervous system (CNS) metastases unless stable 2 months post definitive therapy with steroids.
• Unresolved AEs of Grade 2 or higher from prior anticancer therapy.
• Past or current history of autoimmune disease or immune deficiency.
• History of other malignancy within 3 years of first study treatment cycle.
• Current or recent treatment with certain therapies including specified anticancer treatments, modulators of CYP3A4 and immunomodulating therapies (prior treatment with CPIs is not exclusory).
• Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test product.
• Clinically significant abnormal laboratory safety tests.

Where it is running

• University of Colorado Hospital- Anschutz Cancer Center Pavillion (ACP) — Aurora, Colorado, United States (enrolling)
• University of Colorado Cancer Center - Highlands Ranch Hospital — Highlands Ranch, Colorado, United States (enrolling)
• Mayo Clinic — Florida City, Florida, United States (enrolling)
• Duke University Medical Center - Duke Cancer Center — Durham, North Carolina, United States (enrolling)
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
• The University of Texas MD Anderson Cancer Center — Texas City, Texas, United States (enrolling)
• The Queen Elizabeth Hospital — Woodville, Adelaide, Australia (enrolling)
• Chris O'brien Lifehouse — Camperdown, New South Wales, Australia (enrolling)
• Westmead Hospital — Westmead, New South Wales, Australia (enrolling)
• Icon Cancer Centre — South Brisbane, Queensland, Australia (enrolling)
• Flinders Medical Centre SA — Bedford Park, South Australia, Australia (enrolling)
• Monash Health — Clayton, Victoria, Australia (enrolling)
• Footscray Hospital - Western Health — Footscray, Victoria, Australia (enrolling)
• Austin Health — Heidelberg, Victoria, Australia (enrolling)
• Alfred Hospital — Melbourne, Victoria, Australia (enrolling)
• Sunshine Hospital - Western Health — Saint Albans, Victoria, Australia (enrolling)
• Sir Charles Gairdner Hospital — Nedlands, Western Australia, Australia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.